Zobrazeno 1 - 10
of 91
pro vyhledávání: '"59"'
Autor:
Baris Turkbey, Peter A. Pinto, Joanna H. Shih, Maria Merino, Peter L. Choyke, Ravi A. Madan, John R. Bright, Stephanie Harmon, Guinevere Chun, Fatima Karzai, Huihui Ye, Amy Hankin, Scott Wilkinson, Anna Couvillon, Marijo Bilusic, Lisa M. Cordes, Nicolas T. Terrigino, David J. VanderWeele, Rosina T. Lis, William L. Dahut, Nicole V. Carrabba, Stephanie M. Walker, Monique N. Williams, James L. Gulley, Adam G. Sowalsky
Publikováno v:
Clin Cancer Res
Purpose: For high-risk prostate cancer, standard treatment options include radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (ADT). Despite definitive therapy, many patients will have disease recurrence. Imaging has the pot
Autor:
Rachel M. Layman, Giuseppe Curigliano, Adam S. Crystal, C Terret, Serena Liao, Komal Jhaveri, Sara Cresta, Yan Ji, N Kundamal, Yoon Sim Yap, François Duhoux, Dejan Juric
Publikováno v:
Cancer Research. 80:PD7-09
Background: The combination of ribociclib (an oral CDK4/6 inhibitor) and ET improved survival outcomes in patients (pts) with ER+ ABC in comparison to single-agent ET. In preclinical models, LSZ102 (an experimental oral SERD) demonstrated synergistic
Publikováno v:
Cancer Epidemiol Biomarkers Prev
Background: U.S. breast cancer incidence has been changing, as have distributions of risk factors, including body mass index (BMI), age at menarche, age at first live birth, and number of live births. Methods: Using data for U.S. women from large nat
Autor:
José Bines, Joseph Gligorov, Emilio Alba, Giorgio Mustacchi, S de Ducla, P Button, Dinesh Chandra Doval, Paulo Cortes
Publikováno v:
Cancer Research. 77:P5-15
BACKGROUND The open-label randomized phase III IMELDA trial demonstrated that adding CAP to maintenance BEV until disease progression after initial BEV + docetaxel (DOC) provides statistically significant and clinically meaningful improvements in bot
Autor:
Jie Wang, Haihua Yang, Yanjun Xu, Yi Hu, Xingya Li, Dingzhi Huang, Wang Lifeng, Xiaoyan Lin, Jianhua Chen, Jun Zhao, Yun Fan, Yanping Hu, Caicun Zhou, Jianying Zhou, Hanying Li, Yong Fang, Qiming Wang, Zhijie Wang
Publikováno v:
Cancer Research. 80:CT083-CT083
Background: Treatment options in 2nd-line extensive-stage small-cell lung cancer (ED-SCLC) setting are very limited. PASSION (NCT03417895) was a phase 2 study of camrelizumab plus apatinib in ED-SCLC after platinum-based chemotherapy. Methods: In the
Autor:
Johannes Ettl, C Huang Bartlett, Yaroslav Shparyk, Ravindranath Patel, S.-B. Kim, Tamás Pintér, Xin-Yun Huang, DJ Slamon, Sophia Randolph, J.P. Crown, Richard S. Finn, Anu Thummala, Sashi Nadanaciva
Publikováno v:
Cancer Research. 76:P4-13
Background Palbociclib (P) is an oral CDK4/6 inhibitor. In PALOMA-1/TRIO-18, a randomized phase 2 trial, addition of P to letrozole (L) significantly prolonged progression-free survival (PFS) (20 mo with P+L vs 10 mo with L alone; HR = 0.488, P=0.000
Autor:
Keunchil Park, Jin Seok Ahn, Jong-Mu Sun, Myung-Ju Ahn, Mi Soon Kim, Hee Jin Cho, Jiae Koh, Kyung Young Lee, Boram Kim
Publikováno v:
Cancer Immunology Research. 7:A138-A138
Background: The factors in tumor microenvironment hinder T-cell activities against tumor cells. The major immunosuppressive cells in tumor sites are myeloid-derived suppressor cell (MDSC), tumor-associated macrophage (TAM), and regulatory T (Treg) ce
Autor:
Raymond C. Bergan, Thai H. Ho, Cha-Mei Tang, Saranya Chumsri, Massimo Cristofanilli, Daniel L. Adams, R. Katherine Alpaugh, Stuart S. Martin, Steven H. Lin, Jeffrey R. Marks, Susan Tsai
Publikováno v:
Cancer Research. 78:2631-2631
Background: We previously demonstrated that cancer associated macrophage-like cells (CAMLs) are cancer specific giant polyploid cells circulating in the blood of patients with solid tumors. Building on our initial discovery, others have shown that th
Autor:
Mitchell J. Frederick, Jeffrey N. Myers, Jing Wang, Vaishnavi Sambandam, Faye M. Johnson, Curtis R. Pickering, Pan Tong, Tuhina Mazumdar, Li Shen
Publikováno v:
Cancer Research. 77:2992-2992
Background: Genomic alterations in the PI3K/mTOR pathway occur in 54% of HNSCC patients. However, clinical trials of PI3K/mTOR pathway inhibitors had limited success even in those tumors with pathway alterations, including PIK3CA mutations. To target
Autor:
Naoto T. Ueno, Rachel Krupa, Yipeng Wang, Takeo Fujii, Debu Tripathy, Carlos H. Barcenas, Ryon P. Graf, James M. Reuben, Lyndsey Dugan, Bora Lim, Jessica Kouw, Angela N. Marx, Dena Marrinucci, Ryan Dittamore
Publikováno v:
Cancer Research. 76:496-496
Background: Androgen receptor (AR) is a nuclear transcription factor and a member of the steroid hormone receptor superfamily that can be detected by immunohistochemical staining in all three subtypes of invasive breast cancer with frequency of >70%